To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

December 15, 2023

Shuttle Pharma Advances Patient-Centric Breakthrough for Glioblastoma Treatment

In a significant step towards enhancing treatment options for brain tumor patients, Shuttle Pharmaceuticals Holdings, Inc. has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Ropidoxuridine, a promising radiation sensitizer. With a patient-focused approach, Ropidoxuridine is designed to improve the effectiveness of radiation therapy (RT) in the treatment of glioblastoma, a challenging brain tumor.

The encouraging news follows positive feedback from the FDA, bringing us one step closer to potential advancements in treating glioblastoma. Pending approval, a Phase II trial will evaluate the safety and efficacy of Ropidoxuridine in combination with radiation therapy, specifically tailored for individuals newly diagnosed with glioblastoma.

The upcoming Phase II trial will center on Ropidoxuridine's potential in treating glioblastoma, focusing on patients with specific genetic characteristics. Shuttle Pharma has received Orphan Drug Designation from the FDA, a recognition that could provide exclusive benefits upon approval, emphasizing the company's commitment to advancing radiation therapies.

If you or a family member are interested in learning more about this upcoming clinical trial or would like to gather additional information about it, EBCI is here to assist you in connecting with the Principal Investigators or research facilities located near you. Please feel free to get in touch with Shreya Prakash by emailing her at or calling/texting 425-436-8688. Alternatively, you can complete our Patient Interest Form, and EBCI will contact you.

Shreya Prakash photo

Shreya Prakash
Clinical Research Coordinator
& Patient Navigator
The EndBrainCancer Initiative
16150 NE 85th St., Suite #201
Redmond, WA 98052


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram